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Abstract
Background: Methicillin resistant Staphylococcus aureus (MRSA) has been considered for many
years a typical nosocomial pathogen. Recently MRSA has emerged as a frequent cause of infections
in the community. More commonly, community-acquired (CA)-MRSA is a cause of infections of the
skin and soft-tissues, but life-threatening infections such as necrotizing pneumonia and sepsis can
occasionally occur.
Case presentation: This report describes an uncommon presentation of invasive CA-MRSA
infection in an adolescent without known risk factors. The presentation was typical for bacterial
meningitis, but the clinical findings also revealed necrotizing pneumonia. Following the development
of deep venous thrombosis, the presence of an inherited trombophilic defect (factor V Leiden) was
detected. The patient was successfully treated with an antibiotic combination including linezolid and
with anticoagulant therapy. CA-MRSA was isolated from both cerebrospinal fluid and blood. The
isolates were resistant to oxacillin and other beta-lactam antibiotics and susceptible to the other
antibiotics tested including erythromycin. Molecular typing revealed that the strains contained the
Panton-Valentine leukocidin genes and type IV SCCmec, and were ST8, spa type t008, and agr type
1. This genetic background is identical to that of the USA300 clone.
Conclusion: This report highlights that meningitis can be a new serious presentation of CA-MRSA
infection. CA-MRSA strains with the genetic background of the USA300 clone are circulating in
Italy and are able to cause severe infections.
Published: 30 April 2008
Annals of Clinical Microbiology and Antimicrobials 2008, 7:11 doi:10.1186/1476-0711-7-
11
Received: 5 February 2008
Accepted: 30 April 2008
This article is available from: http://www.ann-clinmicrob.com/content/7/1/11
© 2008 Valentini et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 6
(page number not for citation purposes)
Annals of Clinical Microbiology and Antimicrobials 2008, 7:11 http://www.ann-clinmicrob.com/content/7/1/11Background
Although considered a typical nosocomial pathogen for a
long time, methicillin resistant Staphylococcus aureus
(MRSA) has recently emerged as a cause of infections in
the community. Most commonly, community-acquired
(CA)-MRSA causes skin and soft-tissue infections [1,2]
while severe and life-threatening infections such as necro-
tizing pneumonia [3], necrotizing fasciitis [4] and severe
sepsis [5] represent rare cases. CA-MRSA strains are glo-
bally spread but their prevalence and distribution vary
from country to country [6]. In the United States, CA-
MRSA isolates have become major community pathogens
[1] and are starting to be introduced into the health-care
system [7]. In that country, most of the recent CA-MRSA
isolates belong to a single clone, that can be identified on
the basis of Pulsed Field Gel Electrophoresis (PFGE) pro-
file and other genotyping characteristics and is designed
USA300 [2]. In Europe, the prevalence of infections due to
CA-MRSA appears to be lower than in the United States,
although recent reports highlight that these infections are
on the rise. In a French hospital the incidence of skin and
soft tissue infections due to CA-MRSA increased from 0%
in 2000 to 6.8% in 2003 [8]. In Copenhagen the number
of MRSA isolates, mainly obtained from community-
acquired skin infections, doubled in less than 1 year, from
2003 to 2004) [9]. Differently from the situation in the
United States where one clone predominates, CA-MRSA
clones circulating in Europe are more diverse and hetero-
geneous [6].
In CA-MRSA isolates mec, the gene coding for methicillin
resistance, is usually contained in the type IV variant of
the genetic element staphylococcal chromosomal cassette
(SCC)mec, that is smaller and probably more mobile than
the other SCCmec elements [10]. CA-MRSA often contains
the Panton-Valentine leukocidin (PVL), a toxin endowed
with the unique ability to kill leukocytes [11]. PVL was
initially associated with skin infections [12] and recently
has been shown to play an essential role in the pathogen-
esis of necrotizing pneumonia [13].
We describe here an uncommon presentation of invasive
CA-MRSA infection, with meningitis, bacteremia and
necrotizing pneumonia in association with deep vein
thrombosis, in a previously healthy adolescent.
Case presentation
A 15-year-old boy presented to the emergency department
with a 4-day history of headache, fever, and lumbar pain
and 1-day history of vomiting. His past clinical history
was unremarkable, with the exception of mild asthma
during childhood. Initial examination showed: tempera-
ture 40°C, heart rate 120 beats/min, respiratory rate 30
breaths/min, blood pressure 120/78 mmHg, mild disori-
entation (Glasgow Coma Scale 14) and meningeal signs.
A small infiltrating skin lesion, partly crusted and partly
purulent, was present on the back. The boy had been on a
trekking vacation in Sicily and the lesion had been report-
edly caused by the backpack on the bare skin. A chest radi-
ogram showed bilateral multiple nodular infiltrates.
Ultrasound examination of the abdomen revealed moder-
ate enlargement of the liver and the spleen. A brain CT
scan was normal. Analysis of blood samples at admission
revealed a white blood cell count of 10,300 cells/mm3
with 86% polymorphonuclear leukocytes. Arterial blood
gas analysis showed moderate hypoxemia (PaO2 of 73 mm
Hg on room air). Blood cultures and a lumbar puncture
were performed. Cerebrospinal fluid (CSF) examination
revealed several red blood cells and a leukocyte count of
600 cells/ml, a protein level of 392 mg/dL, and a normal
glucose level. Antibiotic therapy with clarithromycin and
ceftriaxone was initiated and the patient was transferred to
the Pediatric Intensive Care Unit (PICU) of another hos-
pital, where his therapy was changed to ampicillin, doxi-
cycline, ceftriaxone and acyclovir. Laboratories studies
revealed a white blood cell count of 8,700 cells/mm3 with
84.8% polymorphonuclear leukocytes, platelet 130,000/
mm3, C-reactive protein 187 mg/l (normal value < 3 mg/
l), prothrombin time 20.90 sec, activated partial throm-
boplastin time 42 sec, international normalized ratio
1.57, fibrinogen 1060 mg/dL (normal range 200–400 mg/
dL), antithrombin III 39.8% (normal range 70–120%),
D-dimer > 4500 ng/ml (normal value < 278 ng/ml). The
patient did not require mechanical ventilation and after
18 hours was discharged from the PICU and readmitted to
the pediatric ward in stable conditions, conscious and still
febrile to 40°C. Blood and CSF cultures from admission
grew MRSA. Ampicillin was discontinued and vancomy-
cin was added. Since fever persisted unabated, on day 5
the antibiotic therapy was switched to teicoplanin (400
mg iv twice a day), linezolid (600 mg iv twice a day) and
rifampicin (600 mg iv once a day). A heart ultrasound
revealed no valvular vegetations. A CT scan showed bilat-
eral lung cavitary lesions suggesting multiple abscesses,
bilateral pleural effusion (Fig. 1), thrombosis of the infe-
rior vena cava below the renal veins, and of both iliac
veins. Low molecular weight heparin was started. The
patient demonstrated gradual clinical improvement, with
slow normalization of temperature and C-reactive protein
concentration. CT scan showed reduction of the nodular
lesions and of the pleural effusion. Abdomen CT scan and
echo-colour Doppler revealed resolution of the venous
thrombosis. The patient completed a 5-week course of
teicoplanin, rifampicin, and linezolid and was discharged
home at day 40 in good general conditions. Anticoagula-
tion was continued for a total of 6 months.
Because of the unusual severity of the infection, underly-
ing immunological or hematological defects were investi-
gated. Quantitative immunoglobulins and subtypes,Page 2 of 6
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mal. The presence of heterozygous factor V Leiden and
prothrombin gene mutation (G20210A) was revealed.
Phenotypic and genotypic characterizations of MRSA
S. aureus was identified by standard microbiological
methods. Antibiotic susceptibility testing was performed
by BD Phoenix™ Automated Microbiology System (Beck-
ton Dickinson) and confirmed by E-test (AB Biodisk,
Solna, Sweden). The species identification and the methi-
cillin resistance status were confirmed by a duplex PCR
targeting the genes nuc and mec [14]. MRSA grew from the
blood and CSF cultures obtained at admission and from a
second blood culture performed after 48 h, before the
institution of vancomycin therapy. The isolates were
resistant to oxacillin but susceptible to non-beta-lactam
antibiotics including erythromycin, clindamycin, cipro-
floxacin, tetracycline, rifampicin, gentamicin, vancomy-
cin, teicoplanin and linezolid. By E-test, the MIC for
vancomycin was 2 μg/ml. Further characterization of the
isolates was obtained by PCR assays and included deter-
mination of the SCCmec type, agr group, and presence of
the PVL genes lukS-PV and lukF-PV [14]. Genotyping of
the strains was obtained by PFGE, Multilocus Sequence
Typing and by sequencing the polymorphic region of pro-
tein A (spa typing) as previously described [14]. The iso-
lates from blood and CSF were identical by PFGE, and
carried SCCmec type IV and the genes coding for PVL.
Molecular typing showed that the strains were spa type
t008, ST8 and agr type 1, characteristics shared by the
USA300 CA-MRSA clone.
Conclusion
The development of a serious infection in a young person
without predisposing conditions is a typical feature of CA-
MRSA infections. However, to our knowledge, this is the
first described case of CA-MRSA infection presenting with
meningitis in an adolescent. The isolation of CA-MRSA
from CSF is not common. CA-MRSA was isolated from the
CSF of a 16-month-old child who died from fulminant
sepsis. She had multiple abscesses in several organs,
including the brain [15]. A case of CA-MRSA meningitis in
an adult subject was mentioned in a study from Hong-
Kong, but apart from the unfavorable outcome, clinical
data are lacking [16]. Another fatal case recently reported,
was that of a woman with a history of furunculosis and
drug addiction, who developed a brain abscess due to CA-
MRSA [17]. In our patient, meningeal symptoms were
predominant at presentation, and the respiratory symp-
toms remained moderate in spite of the large involvement
of the lungs as demonstrated by CT scan. The patient did
not present airways hemorrhage, nor leukopenia, both
factors being associated with fatal outcome in necrotizing
pneumonia [18]. The skin infection on the patient's back
might have represented the initial source for hematoge-
nous spread of CA-MRSA, although microbiological
examination of the purulent secretion was not performed.
Bacteremia due to typical CA-MRSA containing the PVL
genes is rare but not exceptional, since typical CA-MRSA
can be isolated from blood in the course of severe sepsis
[5] or in other serious CA-MRSA infections in children
and adolescents [19,20]. In an unselected patient popula-
tion, bloodstream infections due to PVL-positive CA-
MRSA are very rare in Europe, as shown in a recent study
from England [21] that included mainly isolates from eld-
erly patients. In the USA, an increasing number of blood-
stream infections in hospitalized patients is due to typical
PVL-positive CA-MRSA [22], probably reflecting the intro-
duction of the USA300 clone in the health-care setting in
that country.
Another remarkable feature of this case is the association
of the invasive CA-MRSA infection with deep venous
thrombosis (DVT). DVT has been increasingly observed in
children in association with osteomyelitis due to S. aureus
containing the PVL genes [23]. Since the presence of PVL
seems to be associated with greater systemic and local
inflammation [20], it has been hypothesized that PVL
could contribute substantially to the development of
DVT. The expression "PVL syndrome" has been proposed
to indicate a multifocal infection including osteomyelitis,
skin infections, pneumonia, and DVT, due to PVL-positive
S. aureus [24]. However, the association between PVL and
DVT has been only observed in acute osteomyelitis and a
causative role for PVL is unproven. In our patient, the CA-
MRSA infection has uncovered inherited trombophilic
Chest CT of a patient with necrotizing pneumonia caused by A-MRSA USA300 geno ypeFigure 1
Chest CT of a patient with necrotizing pneumonia 
caused by CA-MRSA USA300 genotype. The CT scan, 
obtained on hospital day 5, shows multiple nodular lesions, 
some with a central cavitation, and bilateral pleural effusion.Page 3 of 6
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mutation, that have determined the development of DVT,
with or without the contribution of PVL. On the other
hand, the presence of heterozygous factor V Leiden is
known to confer protection in the septic state and
decrease sepsis-related mortality [25], therefore it can
have contributed to the favorable outcome of this case.
The CA-MRSA strain involved had genotypic characteristic
(agr type 1, ST8, t008) of the USA300 clone that has
become the predominant CA-MRSA clone in the USA. In
Europe, the most common clone is the "European clone",
characterized by agr type 3 and ST80 [26], and typically
resistant to fusidic acid [27]. Recently, strains with the
USA300 genotype are starting to be isolated with increas-
ing frequency in various European countries [6]. In Ger-
many, CA-MRSA isolates with the characteristics of the
USA300 clone have become the second most frequent,
after the ST80 isolates [28]. In Italy, a strain with the gen-
otyping characteristics of the USA300 clone was recently
recognized as the cause of a serious skin infection in a
child [29].
The empirical therapy started for meningitis and commu-
nity acquired pneumonia in this patient, that included
ceftriaxone and clarithromycin, is ineffective against
MRSA. In addition, ceftriaxone and beta-lactam antibiot-
ics in general have been shown to increase the expression
of PVL by S. aureus [30], thus potentially worsening the
disease. When the results of the antibiotic susceptibility
tests were available, vancomycin was started. However,
since the vancomycin MIC of the isolate was at the break-
point for susceptibility (2 μg/ml) and the patient's condi-
tion remained critical, a different antibiotic combination
including linezolid was started. Linezolid was chosen
because of its high antistaphylococcal activity, and its
excellent CSF and lung tissue penetration. As in the previ-
ously described case of necrotizing pneumonia [14], line-
zolid therapy likely contributed to the favorable
resolution of the CA-MRSA infection.
The antibiotic treatment of this patient raises several ques-
tions and reflects the lack of evidence-based data to guide
the choice for the treatment of serious CA-MRSA infec-
tions. Vancomycin was used as the first-line treatment
since it is effective against MRSA, and has been widely
used in the past. Although vancomycin penetration in CSF
is low, concentrations of 6–11 μg/ml are usually reached
with inflamed meninges [31] and vancomycin is currently
recommended in the antibiotic combination for the
empirical treatment of bacterial meningitis [32]. The
patient had also pneumonia and it is known that the lev-
els reached by vancomycin in the lung compartment can
be variable and insufficient for a bactericidal effect [31].
Poor penetration into the infected sites was a particularly
critical issue in this case, since the MIC for vancomycin of
the isolates was 2 μg/ml, that is still in the susceptibility
range but close to the breakpoint. Clinical failures have
been reported in serious infections due to MRSA with
reduced susceptibility to vancomycin [33].
All the above conditions might have determined the lack
of clinical improvement of the patient. Therefore, a new
antibiotic combination was attempted, including teico-
planin, rifampicin and linezolid. Although there are few
clinical studies relating to the use of teicoplanin in men-
ingitis, in a rabbit model of MRSA meningitis the antibac-
terial activity of vancomycin and teicoplanin was shown
to be similar [34]. Recent studies have shown the efficacy
of linezolid in the treatment of patients with central nerv-
ous system infections [35] and pneumonia [36], its effi-
cacy being at least equivalent and in some instances
superior, to that of vancomycin. The drug combination
was chosen based on the in vitro susceptibilities of the iso-
lates but no adjunctive in vitro tests were performed to
show whether the combination had synergistic, additive
or antagonistic activity. There are no published clinical
studies with this antibiotic combination to support the
choice.
This case adds a new clinical presentation to CA-MRSA
infections and highlights the problems encountered in the
choice of the therapy of serious community-acquired
infections in the CA-MRSA era.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
PV participated in the design of the study and helped
drafting the manuscript. GP conceived of the study and
performed the antibiotic susceptibility of the bacterial iso-
lates. MM carried out the molecular typing of the isolates.
FC collected and analyzed the clinical data of the patient.
TS contributed to the identification and antibiotic suscep-
tibility of the isolates. OR produced the hematological
data of the patient and participated in the coordination of
the study. MT participated in the design of the study. AP
coordinated the study and drafted the manuscript. All
authors read and approved the final manuscript.
Consent
Written informed consent was obtained from the patient's
parent for publication of this case report and of the
accompanying image. A copy of the written consent is
available for review by the Editor-in-Chief of this journal.
Acknowledgements
This study was supported in part by a grant from the Italian Ministry of Edu-
cation, Research and Technology (FIRB 2005).Page 4 of 6
(page number not for citation purposes)
Annals of Clinical Microbiology and Antimicrobials 2008, 7:11 http://www.ann-clinmicrob.com/content/7/1/11References
1. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK,
Carey RB, Talan DA: Methicillin-resistant Staphylococcus
aureus infections among patients in the emergency depart-
ment.  N Engl J Med 2006, 355(7):666-674.
2. King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg
HM: Emergence of community-acquired methicillin-resistant
Staphylococcus aureus USA 300 clone as the predominant
cause of skin and soft-tissue infections.  Ann Intern Med 2006,
144(5):309-317.
3. Francis JS, Doherty MC, Lopatin U, Johnston CP, Sinha G, Ross T, Cai
M, Hansel NN, Perl T, Ticehurst JR, Carroll K, Thomas DL, Nuer-
mberger E, Bartlett JG: Severe community-onset pneumonia in
healthy adults caused by methicillin-resistant Staphylococ-
cus aureus carrying the Panton-Valentine leukocidin genes.
Clin Infect Dis 2005, 40(1):100-107.
4. Miller LG, Perdreau-Remington F, Rieg G, Mehdi S, Perlroth J, Bayer
AS, Tang AW, Phung TO, Spellberg B: Necrotizing fasciitis caused
by community-associated methicillin-resistant Staphylococ-
cus aureus in Los Angeles.  N Engl J Med 2005,
352(14):1445-1453.
5. Gonzalez BE, Martinez-Aguilar G, Hulten KG, Hammerman WA,
Coss-Bu J, Avalos-Mishaan A, Mason EO Jr., Kaplan SL: Severe sta-
phylococcal sepsis in adolescents in the era of community-
acquired methicillin-resistant Staphylococcus aureus.  Pediat-
rics 2005, 115(3):642-648.
6. Tristan A, Bes M, Meugnier H, Lina G, Bozdogan B, Courvalin P,
Reverdy ME, Enright MC, Vandenesch F, Etienne J: Global distribu-
tion of Panton-Valentine leukocidin-positive methicillin-
resistant Staphylococcus aureus, 2006.  Emerg Infect Dis 2007,
13(4):594-600.
7. Seybold U, Kourbatova EV, Johnson JG, Halvosa SJ, Wang YF, King
MD, Ray SM, Blumberg HM: Emergence of community-associ-
ated methicillin-resistant Staphylococcus aureus USA300
genotype as a major cause of health care–associated blood
stream infections.  Clin Infect Dis 2006, 42:647-656.
8. Del Giudice P, Blanc V, Durupt F, Bes M, Martinez JP, Counillon E,
Lina G, Vandenesch F, Etienne J: Emergence of two populations
of methicillin-resistant Staphylococcus aureus with distinct
epidemiological, clinical and biological features, isolated
from patients with community-acquired skin infections.  Br J
Dermatol 2006, 154(1):118-124.
9. Bartels MD, Boye K, Larsen AR, Skov R, Westh H: Rapid increase
of genetically-diverse methicillin-resistant Staphylococcus
aureus, Copenhagen, Denmark.  Emerg Infect Dis 2007,
13:1533-1540.
10. Pantosti A, Sanchini A, Monaco M: Mechanisms of antibiotic
resistance in Staphylococcus aureus.  Future Microbiol 2007,
2:323-334.
11. Boyle-Vavra S, Daum RS: Community-acquired methicillin-
resistant Staphylococcus aureus: the role of Panton-Valen-
tine leukocidin.  Lab Invest 2007, 87(1):3-9.
12. Yamasaki O, Kaneko J, Morizane S, Akiyama H, Arata J, Narita S,
Chiba J, Kamio Y, Iwatsuki K: The association between Staphy-
lococcus aureus strains carrying Panton-Valentine leukoci-
din genes and the development of deep-seated follicular
infection.  Clin Infect Dis 2005, 40(3):381-385.
13. Labandeira-Rey M, Couzon F, Boisset S, Brown EL, Bes M, Benito Y,
Barbu EM, Vazquez V, Hook M, Etienne J, Vandenesch F, Bowden MG:
Staphylococcus aureus Panton Valentine leukocidin causes
necrotizing pneumonia.  Science 2007, 315:1130-1133.
14. Monaco M, Antonucci R, Palange P, Venditti M, Pantosti A: Methicil-
lin-resistant Staphylococcus aureus necrotizing pneumonia.
Emerg Infect Dis 2005, 11(10):1647-1648.
15. Centers for Disease Control and Prevention (CDC): Four pediatric
deaths from community-acquired methicillin-resistant  Sta-
phylococcus aureus - Minnesota and North Dakota, 1997-
1999.  MMWR Morb Mortal Wkly Rep 1999, 48:707-710.
16. Ho PL, Cheung C, Mak GC, Tse CW, Ng TK, Cheung CH, Que TL,
Lam R, Lai RW, Yung RW, Yuen KY: Molecular epidemiology and
household transmission of community-associated methicil-
lin-resistant Staphylococcus aureus in Hong Kong.  Diagn
Microbiol Infect Dis 2007, 57(2):145-151.
17. Sifri CD, Park J, Helm GA, Stemper ME, Shukla SK: Fatal brain
abscess due to community-associated methicillin-resistant
Staphylococcus aureus strain USA300.  Clin Infect Dis 2007,
45(9):e113-7.
18. Gillet Y, Venhems P, Lina G, Bes M, Vandenesch F, Floret D, Etienne
J: Factors predicting mortality in necrotizing community-
acquired pneumonia caused by Panton-Valentine leukocidin.
Clin Infect Dis 2007, 45:315-321.
19. Adem PV, Montgomery CP, Husain AN, Koogler TK, Arangelovich V,
Humilier M, Boyle-Vavra S, Daum RS: Staphylococcus aureus sep-
sis and the Waterhouse-Friderichsen syndrome in children.
N Engl J Med 2005, 353(12):1245-1251.
20. Bocchini CE, Hulten KG, Mason EO Jr., Gonzalez BE, Hammerman
WA, Kaplan SL: Panton-Valentine leukocidin genes are associ-
ated with enhanced inflammatory response and local disease
in acute hematogenous Staphylococcus aureus osteomyeli-
tis in children.  Pediatrics 2006, 117(2):433-440.
21. Ellington MJ, Hope R, Ganner M, Ganner M, East C, Brick G, Kearns
AM: Is Panton-Valentine leucocidin associated with the
pathogenesis of Staphylococcus aureus bacteraemia in the
UK?  J Antimicrob Chemother 2007, 60(2):402-405.
22. Popovich KJ, Weinstein RA, Hota B: Are community-associated
methicillin-resistant Staphylococcus aureus (MRSA) strains
replacing traditional nosocomial MRSA strains?  Clin Infect Dis
2008, 46(6):787-794.
23. Gonzalez BE, Teruya J, Mahoney DH Jr., Hulten KG, Edwards R, Lam-
berth LB, Hammerman WA, Mason EO Jr., Kaplan SL: Venous
thrombosis associated with staphylococcal osteomyelitis in
children.  Pediatrics 2006, 117(5):1673-1679.
24. Swaminathan A, Massasso D, Gotis-Graham I, Gosbell I: Fulminant
methicillin-sensitive Staphylococcus aureus infection in a
healthy adolescent, highlighting 'Panton-Valentine leucoci-
din syndrome'.  Intern Med J 2006, 36:744-747.
25. Yan SB, Nelson DR: Effect of factor V Leiden polymorphism in
severe sepsis and on treatment with recombinant human
activated protein C.  Crit Care Med 2004, 32(5 Suppl):S239-46.
26. Vandenesch F, Naimi T, Enright MC, Lina G, Nimmo GR, Heffernan
H, Liassine N, Bes M, Greenland T, Reverdy ME, Etienne J: Commu-
nity-acquired methicillin-resistant Staphylococcus aureus
carrying Panton-Valentine leukocidin genes: worldwide
emergence.  Emerg Infect Dis 2003, 9(8):978-984.
27. Witte W, Braulke C, Cuny C, Strommenger B, Werner G, Heuck D,
Jappe U, Wendt C, Linde HJ, Harmsen D: Emergence of methicil-
lin-resistant Staphylococcus aureus with Panton-Valentine
leukocidin genes in central Europe.  Eur J Clin Microbiol Infect Dis
2005, 24(1):1-5.
28. Witte W, Strommenger B, Cuny C, Heuck D, Nuebel U: Methicillin-
resistant Staphylococcus aureus containing the Panton-Val-
entine leucocidin gene in Germany in 2005 and 2006.  J Antimi-
crob Chemother 2007, 60(6):1258-1263.
29. Tinelli M, Pantosti A, Lusardi C, Vimercati M, Monaco M: First
detected case of community-acquired methicillin-resistant
Staphylococcus aureus skin and soft tissue infection in Italy.
Euro Surveill 2007, 12(4):E0704121.
30. Dumitrescu O, Boisset S, Badiou C, Bes M, Benito Y, Reverdy ME,
Vandenesch F, Etienne J, Lina G: Effect of antibiotics on Staphy-
lococcus aureus producing Panton-Valentine leukocidin.
Antimicrob Agents Chemother 2007, 51(4):1515-1519.
31. Rybak MJ: The pharmacokinetic and pharmacodynamic prop-
erties of vancomycin.  Clin Infect Dis 2006, 42 Suppl 1:S35-9.
32. Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld
WM, Whitley RJ: Practice guidelines for the management of
bacterial meningitis.  Clin Infect Dis 2004, 39(9):1267-1284.
33. Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P,
Grabsch EA, Roberts SA, Robson J, Read K, Bak N, Hurley J, Johnson
PD, Morris AJ, Mayall BC, Grayson ML: Treatment outcomes for
serious infections caused by methicillin-resistant Staphylo-
coccus aureus with reduced vancomycin susceptibility.  Clin
Infect Dis 2004, 38(4):521-528.
34. Sipahi OR, Arda B, Yurtseven T, Sipahi H, Ozgiray E, Suntur BM, Ulu-
soy S: Vancomycin versus teicoplanin in the therapy of exper-
imental methicillin-resistant Staphylococcus aureus (MRSA)
meningitis.  Int J Antimicrob Agents 2005, 26(5):412-415.Page 5 of 6
(page number not for citation purposes)
Annals of Clinical Microbiology and Antimicrobials 2008, 7:11 http://www.ann-clinmicrob.com/content/7/1/11Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
35. Ntziora F, Falagas ME: Linezolid for the treatment of patients
with central nervous system infection.  Ann Pharmacother 2007,
41(2):296-308.
36. Kohno S, Yamaguchi K, Aikawa N, Sumiyama Y, Odagiri S, Aoki N,
Niki Y, Watanabe S, Furue M, Ito T, Croos-Dabrera R, Tack KJ: Lin-
ezolid versus vancomycin for the treatment of infections
caused by methicillin-resistant Staphylococcus aureus in
Japan.  J Antimicrob Chemother 2007, 60(6):1361-1369.Page 6 of 6
(page number not for citation purposes)
